You just read:

Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer

News provided by

Daiichi Sankyo Company, Limited

24 Sep, 2018, 15:30 BST